Astrazeneca plc (AZN) RNS Announcements

Date	Time	Date	TitleTitle (filtered)	Source
20/12/18	13:47:36	20 Dec 2018	Bevespi Aerosphere approved in the EU for COPD	Bevespi Aerosphere approved in the EU for COPD	RNS
20/12/18	07:05:00	20 Dec 2018	Lynparza meets primary endpoint in SOLO-3 trial	Lynparza meets primary endpoint in SOLO-3 trial	RNS
20/12/18	07:00:06	20 Dec 2018	Phase III ROCKIES and OLYMPUS roxadustat trials	Phase III ROCKIES and OLYMPUS roxadustat trials	RNS
19/12/18	18:31:28	19 Dec 2018	FDA approves Lynparza as 1L maintenance therapy	FDA approves Lynparza as 1L maintenance therapy	RNS
18/12/18	09:09:45	18 Dec 2018	Roxadustat approved in China for the treatment of	Roxadustat approved in China for the treatment of	RNS
14/12/18	07:00:03	14 Dec 2018	Directorate Change	Directorate Change	RNS
07/12/18	07:00:05	7 Dec 2018	Update on the Phase III EAGLE trial of Imfinzi	Update on the Phase III EAGLE trial of Imfinzi	RNS
06/12/18	07:00:02	6 Dec 2018	Divestment of rights to Covis completed	Divestment of rights to Covis completed	RNS
04/12/18	15:00:02	4 Dec 2018	Director/PDMR Shareholding	Director/PDMR Shareholding	RNS
03/12/18	16:00:01	3 Dec 2018	Block listing Interim Review	Block listing Interim Review	RNS
03/12/18	16:00:01	3 Dec 2018	Total Voting Rights	Total Voting Rights	RNS
03/12/18	07:00:05	3 Dec 2018	Grünenthal Agreement for Nexium, Vimovo Completed	Grünenthal Agreement for Nexium, Vimovo Completed	RNS
26/11/18	07:00:06	26 Nov 2018	US FDA grants Fasenra ODD for EGPA	US FDA grants Fasenra ODD for EGPA	RNS
16/11/18	07:00:04	16 Nov 2018	AstraZeneca provides update on Phase III MYSTIC	AstraZeneca provides update on Phase III MYSTIC	RNS
13/11/18	07:00:12	13 Nov 2018	AstraZeneca to divest US Synagis rights to Sobi	AstraZeneca to divest US Synagis rights to Sobi	RNS
12/11/18	07:05:03	12 Nov 2018	US FDA accepts regulatory submission for Lynparza	US FDA accepts regulatory submission for Lynparza	RNS
12/11/18	07:00:04	12 Nov 2018	Farxiga significantly reduced hospitalisation for	Farxiga significantly reduced hospitalisation for	RNS
08/11/18	07:00:09	8 Nov 2018	AZN: Year-to-Date and Q3 2018 Results	AZN: Year-to-Date and Q3 2018 Results	RNS
06/11/18	07:00:10	6 Nov 2018	Divestment of rights to Covis Pharma	Divestment of rights to Covis Pharma	RNS
01/11/18	15:00:01	1 Nov 2018	Total Voting Rights	Total Voting Rights	RNS
31/10/18	09:45:02	31 Oct 2018	Additional financial information-Grünenthal deal	Additional financial information-Grünenthal deal	RNS
30/10/18	07:00:08	30 Oct 2018	Grünenthal Agreement for rights to Nexium, Vimovo	Grünenthal Agreement for rights to Nexium, Vimovo	RNS
23/10/18	08:00:06	23 Oct 2018	AstraZeneca Extends Innate Pharma Collaboration	AstraZeneca Extends Innate Pharma Collaboration	RNS
22/10/18	08:00:06	22 Oct 2018	Lynparza shows 70% reduction in PFS ovarian cancer	Lynparza shows 70% reduction in PFS ovarian cancer	RNS
19/10/18	14:09:23	19 Oct 2018	CHMP positive opinion Bevespi Aerosphere	CHMP positive opinion Bevespi Aerosphere	RNS
16/10/18	08:00:10	16 Oct 2018	FDA Orphan Drug for Lynparza in pancreatic cancer	FDA Orphan Drug for Lynparza in pancreatic cancer	RNS
01/10/18	16:00:02	1 Oct 2018	Total Voting Rights	Total Voting Rights	RNS
01/10/18	08:00:05	1 Oct 2018	Atacand Agreement with Cheplapharm Completed	Atacand Agreement with Cheplapharm Completed	RNS
28/09/18	17:00:03	28 Sept 2018	Previous Announcement Regarding Appointment Of NED	Previous Announcement Regarding Appointment Of NED	RNS
25/09/18	14:15:01	25 Sept 2018	Overall survival data for Imfinzi: Stage III NSCLC	Overall survival data for Imfinzi: Stage III NSCLC	RNS
24/09/18	17:10:01	24 Sept 2018	EMA approves AZ's Imfinzi for Stage III NSCLC	EMA approves AZ's Imfinzi for Stage III NSCLC	RNS
24/09/18	08:00:12	24 Sept 2018	Farxiga gets positive result in DECLARE-TIMI 58	Farxiga gets positive result in DECLARE-TIMI 58	RNS
07/09/18	08:00:03	7 Sept 2018	Tezepelumab FDA Breakthrough Therapy Designation	Tezepelumab FDA Breakthrough Therapy Designation	RNS
03/09/18	16:00:02	3 Sept 2018	Total Voting Rights	Total Voting Rights	RNS
31/08/18	08:00:05	31 Aug 2018	AstraZeneca Update on Anifrolumab in SLE	AstraZeneca Update on Anifrolumab in SLE	RNS
30/08/18	08:00:07	30 Aug 2018	EC approves Bydureon BCise device for T2 diabetes	EC approves Bydureon BCise device for T2 diabetes	RNS
23/08/18	08:00:05	23 Aug 2018	AstraZeneca PIIIb trial update for Bevespi in COPD	AstraZeneca PIIIb trial update for Bevespi in COPD	RNS
21/08/18	08:00:09	21 Aug 2018	AZ's Tagrisso approved in Japan for 1st-line NSCLC	AZ's Tagrisso approved in Japan for 1st-line NSCLC	RNS
15/08/18	08:00:03	15 Aug 2018	AstraZeneca prices a $3bn bond issue	AstraZeneca prices a $3bn bond issue	RNS
03/08/18	08:00:01	3 Aug 2018	EMA grants OD for selumetinib in NF1	EMA grants OD for selumetinib in NF1	RNS
01/08/18	16:00:03	1 Aug 2018	Total Voting Rights	Total Voting Rights	RNS
27/07/18	15:00:03	27 Jul 2018	CHMP recommends Imfinzi for Stage III nsclc	CHMP recommends Imfinzi for Stage III nsclc	RNS
26/07/18	08:00:10	26 Jul 2018	AZN: H1 2018 Results	AZN: H1 2018 Results	RNS
24/07/18	08:00:10	24 Jul 2018	Atacand to be divested to Cheplapharm in Europe	Atacand to be divested to Cheplapharm in Europe	RNS
18/07/18	17:11:58	18 Jul 2018	Holding(s) in Company	Holding(s) in Company	RNS
02/07/18	16:00:02	2 Jul 2018	Total Voting Rights	Total Voting Rights	RNS
02/07/18	08:00:03	2 Jul 2018	Lynparza approved in Japan for BRCAm breast cancer	Lynparza approved in Japan for BRCAm breast cancer	RNS
02/07/18	08:00:03	2 Jul 2018	Imfinzi approved in Japan for Stage III nsclc	Imfinzi approved in Japan for Stage III nsclc	RNS
29/06/18	16:00:02	29 Jun 2018	Bydureon receives positive CHMP opinion for BCise	Bydureon receives positive CHMP opinion for BCise	RNS
28/06/18	14:30:01	28 Jun 2018	AZ and Luye Pharma complete agreement for Seroquel	AZ and Luye Pharma complete agreement for Seroquel	RNS

Showing 851–900 of 1,436 announcements

Astrazeneca plc RNS

Astrazeneca plc RNS